Asieris Pharmaceuticals, in accordance with advice from the National Medical products Administration Center for Drug Evaluation (CDE), has approved the inclusion of Asieris’s drug Hexvic®, a drug for the diagnosis of bladder cancer, in the clinical real-world world evidence pilot study, making it ninth drug to take part in such study. According to the 2020 global cancer data released by the World Health Organization’s International Agency for Research on Cancer (IARC), bladder cancer is one of the top 10 cancers with the highest incidents in the world.
Hexvix® has been approved In the United States and many European countries. The combined use of Hexvix® and blue light cystoscopy (BLC) for the management of non-muscle invasive bladder cancer (NMIBC) has been included in the global expert consensus guidelines and Chinese Urological Association Guideline. Read more here.